UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)

SIGYN THERAPEUTICS INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.0001

(Title of Class of Securities)

82674U106

(CUSIP Number)

December 31, 2020

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: 🗵 Rule 13d-1(c)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s)

Page 1 of 5 Pages

CUSIF	No. 82674U106		13G	Page 2 of 5 Pages		
1.	NAMES OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON					
	5.5. OK 1.K.5. I	S.S. OK I.K.S. IDENTIFICATION NO. OF ABOVE PERSON				
	Alpha Capital A					
2.	CHECK THE A					
	(a) □					
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Liechtenstein					
	Liechtenstein	5.	SOLE VOTING POWER – 0 Shares			
N	UMBER OF	5.	SOLE VOTING FOWER - U Shares			
IN	SHARES	6.	SHARED VOTING POWER - None			
	NEFICIALLY WNED BY EACH EPORTING					
		7.	SOLE DISPOSITIVE POWER – 0 Shares			
R						
	PERSON	8.	SHARED DISPOSITIVE POWER – None			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -					
	0 Shares					
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
10.	CHECK BOA II THE AGOREGATE AMOUNT IN ROW (7) EACLODES CERTAIN SHARES []					
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
	0%					
12.	TYPE OF REPORTING PERSON					

CUSIP No	. 82674U106	13G	Page 3 of 5 Page
TEM 1 (a)	NAME OF ISSUER: Sigyn Therapeutics	s Inc.	
TEM 1 (b)	ADDRESS OF ISSUER'S PRINCIPAL	EXECUTIVE OFFICES:	
	9465 Wilshire Boulevard, Beverly Hills,	CA 90212	
TEM 2 (a)	NAME OF PERSON FILING: Alpha Ca	apital Anstalt	
ГЕМ 2 (b)	ADDRESS OF PRINCIPAL BUSINESS	S OFFICE OR, IF NONE, RESIDENCE:	
	Lettstrasse 32, FL-9490 Vaduz, Furstent	ums, Liechtenstein	
ГЕМ 2 (c)	CITIZENSHIP: Liechtenstein		
ГЕМ 2 (d)	TITLE OF CLASS OF SECURITIES: C	Common Stock, par value \$0.0001	
TEM 2 (e)	CUSIP NUMBER: 82674U106		
TEM 3	IF THIS STATEMENT IS FILED PURS	SUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable	
TEM 4	OWNERSHIP		
	(a) AMOUNT BENEFICIALLY OWN	ED: 0 Shares	
	(b) PERCENT OF CLASS: 0%		
	(c) NUMBER OF SHARES AS TO WI	HICH SUCH PERSON HAS:	
	(i) SOLE POWER TO VOTE OR	DIRECT THE VOTE	
	0 Shares		
	(ii) SHARED POWER TO VOTE	OR DIRECT THE VOTE	
	0 Shares		
	(iii) SOLE POWER TO DISPOSE (OR TO DIRECT THE DISPOSITION OF	
	0 Shares		
	(iv) SHARED POWER TO DISPOS	SE OR TO DIRECT THE DISPOSITION OF	
	0 Shares		
CUSIP No	. 82674U106	13G	Page 4 of 5 Page

ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

Not applicable

ITEM 9 NOTICE OF DISSOLUTION OF GROUP

Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 13, 2021 (Date)

/s/ Konrad Ackermann (Signature)

Konrad Ackermann, Director (Name/Title)